BioMedNewsBreaks

ThursdaySep 04, 2025 12:54 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Data Demonstrating Two-Year Stability of ThermoVax Ebolavirus Vaccines

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the publication of new data showing extended stability of its ebolavirus vaccines developed with the ThermoVax(R) platform. Bivalent and trivalent vaccines formulated from Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus antigens retained full potency after two years of storage at up to 40°C (104°F), according to a manuscript accepted by Vaccine. Developed in collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa, the thermostable vaccines have demonstrated robust immune responses in animal models, with up to 100% protection in non-human primates. Soligenix noted that ThermoVax…

Continue Reading

ThursdaySep 04, 2025 12:39 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Preclinical Data Showing CNM-Au8 Improves Cellular Health in Parkinson’s Disease Model 

Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc., announced new preclinical data demonstrating that CNM-Au8(R) improved mitochondrial function, reduced inflammation, and restored cellular metabolism in a novel dopaminergic neuron model of Parkinson’s disease (PD). The findings, presented at the Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting in New York City, showed CNM-Au8 corrected metabolic imbalances, normalized dysregulated gene expression, and exhibited a favorable safety profile with no toxicity observed in PD neurons. Conducted in collaboration with the Salk Institute and supported by MJFF funding, the study underscores CNM-Au8’s potential as a neuroprotective therapy for both familial…

Continue Reading

ThursdaySep 04, 2025 10:58 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights CEO Dr. Vuong Trieu’s Impact and Clinical Pipeline Progress

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments, provided an update on its pipeline while recognizing the contributions of Chairman and CEO Dr. Vuong Trieu. Dr. Trieu has filed more than 500 patents and holds 75 issued patents spanning biologics, small molecules, nanoparticles and diagnostics. He co-invented and developed Abraxane (nab-paclitaxel), acquired by Celgene in a $2.9 billion transaction, and later sold Cynviloq (nanoparticle paclitaxel) to NantPharma in a $1.3 billion deal. His career achievements extend across multiple therapeutic areas with a focus on advancing first-in-class treatments for high unmet medical needs. To view the…

Continue Reading

ThursdaySep 04, 2025 10:18 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Subsidiary Publishes Landmark Primer on Oncology Real-World Evidence

Fifty 1 Labs (OTC: FITY) through its subsidiary Fifty1 AI Labs, announced the publication of a landmark technical primer on transportability methods in oncology real-world evidence (RWE) in the Journal of Comparative Effectiveness Research. Co-authored by CTO Alind Gupta and CEO Paul Arora, the paper showcases how advanced statistical and AI-driven frameworks can bridge data gaps, accelerate health technology assessments, and improve global access to life-saving therapies. With the oncology RWE market projected to expand from $789 million in 2024 to $3.51 billion by 2035 at a CAGR of 14.7%, the publication underscores Fifty1 Labs’ leadership in advancing drug repurposing…

Continue Reading

ThursdaySep 04, 2025 9:50 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) CEO Featured on IBN’s BioMedWire Podcast

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing the IzoView Breast CT Imaging System, was featured in the latest episode of IBN’s BioMedWire Podcast. CEO Robert Thast discussed the company’s mission to improve early breast cancer detection, noting IzoView’s ability to identify cancers as small as 2 millimeters compared to the 11-millimeter average under current standards of care. Thast also outlined Izotropic’s intellectual property portfolio, AI-driven advancements, competitive outlook, and commercialization strategy in Europe and the U.S., adding that the company could be a takeover target as demand for innovative breast imaging solutions grows. To view…

Continue Reading

ThursdaySep 04, 2025 9:20 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures $5.3 Million from Warrant Exercises to Advance AVERSA Fentanyl NDA

Nutriband (NASDAQ: NTRB), a company developing abuse deterrent pharmaceutical products, announced the exercise of warrants at a strike price of $6.43, generating $5,306,000 in proceeds. The funds will support the remaining clinical development of AVERSA Fentanyl and submission of its New Drug Application (NDA) with the U.S. Food and Drug Administration. AVERSA Fentanyl, which could become the world’s first opioid patch with abuse deterrent properties, is estimated to reach peak annual U.S. sales of $80 million to $200 million, according to a 2022 Health Advances market analysis report. To view the full press release, visit https://ibn.fm/7olqo About Nutriband Inc. We…

Continue Reading

WednesdaySep 03, 2025 1:45 pm

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Completes FDA Type C Meeting, Gains Guidance for Planned Pediatric CNS Cancer Trial 

Lantern Pharma (NASDAQ: LTRN), an AI-driven clinical-stage oncology company, announced the completion of a Type C meeting with the U.S. Food and Drug Administration, which provided guidance on the regulatory pathway and design of a planned pediatric trial targeting CNS cancers, including Atypical Teratoid Rhabdoid Tumor (ATRT). The FDA supported Lantern’s proposal for a parallel ATRT cohort and the potential inclusion of spironolactone as a combination agent with LP-184/STAR-001, the company’s lead investigational therapy. Lantern, through its subsidiary Starlight Therapeutics, will submit an IND amendment reflecting the feedback, with trial initiation targeted for Q1 2026. The program holds Rare Pediatric…

Continue Reading

WednesdaySep 03, 2025 1:10 pm

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join H.C. Wainwright’s 27th Annual Global Investment Conference; CEO Fireside Chat Set for Sept. 8, 2025, 4:30 to 5 p.m. ET

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc. (“HOPE”), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, announced that Chairman and CEO Jonathan Javitt, M.D., M.P.H., will participate in a fireside chat at H.C. Wainwright’s 27th Annual Global Investment Conference on Monday, Sept. 8, 2025, from 4:30 to 5 p.m. ET. A webcast will be available on the Events page of the Investors section of the Company’s website, with a replay posted two hours after the event for 30 days. To view the full press release, visit https://ibn.fm/Ycyhk About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc.…

Continue Reading

WednesdaySep 03, 2025 9:30 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Secures Exclusive U.S. Patent for Computer-Aided Diagnosis with Breast CT

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company commercializing imaging-based technologies for improved breast cancer screening, diagnosis, and treatment, announced the issuance of the only U.S. patent for computer-aided diagnosis (CADx) with breast CT, covered under the Company’s exclusive global license agreement with the Regents of the University of California. CADx is an AI software tool that analyzes medical images to estimate malignancy likelihood and support radiologists in interpreting scans. In breast imaging, CADx is being developed to address limitations of mammography, digital breast tomosynthesis, ultrasound, and MRI by detecting subtle abnormalities, improving diagnostic consistency, reducing read…

Continue Reading

TuesdaySep 02, 2025 12:30 pm

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports First-Half 2025 Results and Strengthened Cash Position

Scinai Immunotherapeutics (NASDAQ: SCNI) reported revenues of $773,000 for the six months ended June 30, 2025, up from $284,000 in the prior-year period, reflecting continued growth in its CDMO business. R&D expenses fell to $1.24 million from $2.79 million, while marketing, general and administrative expenses rose to $1.26 million from $1.00 million. Net loss narrowed to $4.13 million compared to $4.48 million a year earlier. Cash and equivalents totaled $989,000 as of June 30, with an additional $4.2 million raised in July and August under the Company’s Standby Equity Purchase Agreement, significantly strengthening liquidity. Scinai advanced its anti-IL-17 NanoAb program,…

Continue Reading